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Introduction: No studies have compared ventilator-associated pneumonia (VAP) and non-VAP following cardiac surgery
(CS). The aim of this study was to assess the incidence, clinical and microbiologic features, treatment characteristics and
prognosis of postoperative pneumonia following CS with a special focus on non-VAP.
Methods: This was a retrospective cohort study based on a prospectively collected database. We compared cases of
non-VAP and VAP following CS observed between January 2005 and December 2012. Statistical analysis consisted of
bivariate and multivariate analysis.
Results: A total of 257 (3.5%) of 7,439 consecutive CS patients developed postoperative pneumonia, including 120
(47%) cases of non-VAP. Patients with VAP had more frequent history of congestive heart failure (31% vs. 17%,
P = 0.006) and longer duration of cardiopulmonary bypass (105 vs 76 min, P < 0.0001), than patients with non-VAP. No
significant differences were observed between the 2 groups in terms of the types of microorganisms isolated with high
proportions of Enterobacteriaceae (35%), Pseudomonas aeruginosa (20.2%) and Haemophilus spp (20.2%), except for a
lower proportion of Methicillin-susceptible S. aureus in the non-VAP group (3.2% vs 7.9%, P = 0.03). In the intensive care
unit, patients with non-VAP had lower sequential organ failure assessment scores than patients with VAP (8 ± 3 versus
9 ± 3, P = 0.004). On multivariate analysis, in-hospital mortality was similar in both groups (32% in the non-VAP group
and 42% in the VAP group, adjusted Odds Ratio (aOR): 1.4; 95% confidence intervals (CI): 0.7-2.5; P = 0.34) and
appropriate empiric antibiotic therapy was associated with a reduction of in-hospital mortality (aOR: 0.4; 95% CI:
0.2-1; P = 0.05). Piperacillin/tazobactam or imipenem monotherapy constituted appropriate empiric therapy in the
two groups, with values reaching 93% and 95% with no differences between VAP and non-VAP cases.
Conclusions: Intensive care patients with VAP are more severely ill than non-VAP patients following CS. Nevertheless,
patients with non-VAP and VAP following CS have similar outcomes. This study suggests that the empiric antibiotic
regimen in patients with pneumonia following CS should include at least a broad-spectrum antibiotic targeting
non-fermenting Gram-negative bacilli, regardless of the type of pneumonia, and targeting S. aureus in VAP patients.* Correspondence: nicolas.allou@hotmail.fr
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Postoperative pneumonia (POP), is the most common
infection following cardiac surgery (CS) [1,2] and con-
stitutes a major source of morbidity and mortality [1,2].
Previous studies confined their analysis to patients with
ventilator-associated pneumonia (VAP) [1-4]. However,
VAP is not the only presentation of postoperative pneu-
monia (POP) following surgery in general (36%) [5] and
CS in particular (57%) [6]. Extrapolation of data on
VAP following CS to non-VAP may, therefore, lead to
significant errors in the management of patients with
non-VAP. The aim of this study was to compare the
characteristics of VAP and non-VAP following CS. In
order to define precisely the clinical characteristics and
antibiotic therapy of these patients, we assessed the in-
cidence, clinical and microbiologic features, treatment
characteristics and prognosis of a group of patients
who developed non-VAP following CS.Materials and methods
Data from consecutive patients who underwent CS with
cardiopulmonary bypass from January 2005 to December
2012 in a 1,200-bed university hospital were included in
this single-center cohort study. Perioperative character-
istics were obtained from our local, prospectively col-
lected database. The study was approved by the local
ethics committee, which waived the need for informed
consent, because of the observational nature of the study
(Institutional Review Board 00006477, Paris 7 University,
AP-HP). Patients on mechanical ventilation before CS
were excluded from the analysis.
Perioperative care, including anesthesia, monitoring
techniques and normothermic cardiopulmonary bypass,
was standardized for all patients. During the study period,
patients received a systematic decolonization protocol
with three doses of intranasal mupirocin per day for 5
consecutive days. Cefamandole (30 mg/kg intravenously
one hour before sternotomy, 750 mg (1,500 mg in patients
with body mass index >35 kg/m2) every two hours during
surgery and continued for 24 hours in the ICU at a dosage
of 750 mg, four times per day) was used for surgical anti-
biotic prophylaxis. In patients with beta-lactam allergy,
antibiotic prophylaxis comprised vancomycin (15 mg/kg
intravenously over 60 minutes one hour before sternot-
omy and 15 mg/kg at the eighth hour) + gentamicin (3
mg/kg intravenously as a single dose). No subsequent
prophylaxis was administered. No subglottic aspiration
system was used. After surgery patients were transferred
to the ICU without systematic postoperative sedation and
were extubated when the standard extubation criteria
were obtained (hemodynamically stable; no significant
bleeding and percutaneous oxygen saturation >95% with
inspired oxygen fraction (FiO2) <0.4).Prevention of postoperative pneumonia included orotra-
cheal intubation, cleaning of the oropharyngeal cavity with
0.1% hexetidine solution (McNeil, Issy-les-Moulineaux,
France) four times per day, semirecumbent body position-
ing (30 to 45°), tracheal cuff pressure maintained between
20 and 30 cm H2O, and physiotherapy (at least twice daily
for 2 days following extubation).
Diagnosis of postoperative pneumonia
Postoperative pneumonia was suspected on the basis
of a new lung infiltrate on daily chest radiographs as-
sociated with at least two of the following findings:
temperature ≥38.3°C or <36°C, white blood cell
count >12,000 cells/mm3 or <5,000 cells/mm3, and
purulent secretion.
Postoperative pneumonia was systematically confirmed
by microbiologic analysis using bronchoalveolar lavage
with fiberoptic bronchoscopy (yielding bacteria at a con-
centration of >104 colony forming units (CFU)/mL) or
blind protected distal bronchial specimen samples (yield-
ing >103 CFU/mL) or blind endotracheal aspiration
(yielding >105 CFU/mL). Only the first episode of pneu-
monia following surgery was studied and was defined as
POP. VAP was defined as pneumonia occurring in pa-
tients with postoperative invasive mechanical ventilation
for 48 hours or longer with the ventilator in place at the
time of or 24 hours before the event [7]. Patients who
developed POP but who did not meet the criteria for
VAP were defined as non-VAP. Early-onset POP was de-
fined as pneumonia with onset <5 days following surgery
and late-onset POP was defined as pneumonia with on-
set ≥5 days following surgery [8].
Susceptibility testing and empiric antimicrobial therapy
Empiric antimicrobial therapy based on local guidelines
was always initiated in the case of suspected POP and
was considered appropriate when all bacteria isolated at
a significant concentration were susceptible to at least
one of the drugs administered, according to susceptibil-
ity testing. The choice of antibiotic therapy was left to
the attending physician and was guided by Gram-stained
direct examination and the severity of pneumonia at the
time of diagnosis. Susceptibility testing was determined
by the disk-diffusion method, according to the criteria of
the Antibiogram Committee of the French Society for
Microbiology [9].
Data collected
Demographic characteristics and underlying diseases were
recorded during the first 24 hours after admission to the
ICU. Intraoperative and postoperative characteristics and
outcome (ICU length of stay and in-hospital mortality)
were also recorded.
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Results were expressed as total numbers (percentage)
for categorical variables and mean ± standard deviation
or median (25th to 75th percentiles) as appropriate for
continuous variables. Continuous variables were com-
pared by the unpaired Student t-test or nonparametric
(Mann-Whitney) test as appropriate. Categorical vari-
ables were compared by the chi-square test or Fisher’s
exact test as appropriate. Risk factors found to be pre-
dictive of postoperative mortality in bivariate analysis
P-values <0.1 were entered into a multivariate logistic
regression analysis using backward selection on a cri-
terion of P <0.05. A P-value <0.05 was considered sig-
nificant. Calibration was assessed using the Hosmer and
Lemeshow goodness-of-fit test. Analysis was performed
using SAS statistical software (8.2, Cary, NC, USA).Results
Study population
From January 2005 to December 2012, 7,468 cardiac pro-
cedures with cardiopulmonary bypass were performed.
Twenty-nine patients were on mechanical ventilation be-
fore surgery and were excluded from the analysis. The
remaining 7,439 patients constituted the cohort. Overall,
257 (3.5%; 95% CI 3.1, 3.9) of 7,439 consecutive CS pa-
tients developed POP including 120 (46.7%) cases of non-
VAP. POP was diagnosed 4.3 ± 2 days after CS in both
groups (P = 0.55). Ninety patients (66%) developed early-
onset POP in the VAP group versus 76 patients (63%) in
the non-VAP group (P = 0.69). Preoperative and intraoper-
ative characteristics of the 257 patients are presented in
Tables 1 and 2.Diagnostic procedures and distribution of microorganisms
Two hundred and sixty-eight respiratory samples were
obtained from these 257 patients. Eleven patients had a
first negative sample (7 protected distal bronchial speci-
men samples, 4 endotracheal aspirations) followed by a
Preoperative characteristicssecond positive sample (11
bronchoalveolar lavage samples); 8 out of 120 (6.7%) pa-
tients in the non-VAP group versus 3 out of 137 (2.2%)
patients in the VAP group (P = 0.08). Microbiologic sam-
ples were obtained with a bronchoscopic method (bron-
choalveolar lavage) in 87 patients (63.5%) in the VAP
group versus 72 patients (60%) in the non-VAP group
(P = 0.56).
A total of 302 microorganisms were cultured at signifi-
cant concentrations (Table 3). Postoperative pneumonia
was polymicrobial in 101 (39.3%) cases with no significant
differences between the two groups of patients (P = 0.29).
The microorganisms most commonly isolated were En-
terobacteriaceae (35.4%), Pseudomonas aeruginosa (20.2%)
and Haemophilus spp (20.2%).No significant differences were observed between the
two groups in terms of the relative proportion of microor-
ganisms isolated except for a lower proportion of
Methicillin-susceptible S. aureus in the non-VAP group
(3.2% versus 7.9%, P = 0.03). No significant differences
were observed between early-onset and late-onset POP in
terms of the microorganisms isolated (P > 0.2 for all iso-
lated microorganisms).
Empiric antibiotic therapy and susceptibility of
microorganisms
Two hundred and four patients had a dual combin-
ation with broad-spectrum antibiotic agents targeting
non-fermenting Gram-negative bacilli (79.4%). The
most commonly prescribed empiric antibiotic regimen
was a combination of piperacillin/tazobactam and ami-
kacin (70.4%) with no significant difference between
the two groups (P = 0.89). A similar rate of appropriate
empiric antimicrobial therapy was observed in the two
groups (87.5% in non-VAP and 89.8% in VAP, P = 0.6).
When empiric antibiotic therapy was inappropriate,
the final antibiotic therapy was modified to achieve ap-
propriateness in every case (2 days after the respiratory
sample). Most microorganisms isolated in this study
cohort were susceptible to antibiotic therapy including
a broad-spectrum antibiotic agent targeting non-
fermenting Gram-negative bacilli (>92%) with no sig-
nificant differences between the two groups of patients
(Table 4).
Outcome
Clinical characteristics of postoperative pneumonia at
the time of diagnosis in the 257 patients are presented
in Table 5.
Among the 120 patients with non-VAP, 93 (78%) re-
quired re-intubation during the 24 hours following the
diagnosis of POP. Of the 257 patients, 95 (37%) died
after heart surgery, including 38 (32%) of the 120 pa-
tients with non-VAP versus 57 (42%) of the 137 patients
with VAP (P = 0.1). Of the 29 patients who received in-
appropriate empiric antibiotic therapy, 18 (62%) died
versus 77 (34%) of the 228 patients with appropriate ini-
tial empiric therapy (P = 0.003).
Risk factors for in-hospital mortality
Fifteen variables had a P-value < 0.10 on univariate ana-
lysis (see Additional file 1 for univariate analysis of risk
factors for in-hospital mortality with P <0.10) and were
entered into the logistic regression (Table 6).
On multivariate analysis (Table 6), in-hospital mortal-
ity was independently associated with a history of con-
gestive heart failure (odds ratio (OR) 2.28, 95% CI 1.17,
4.46, P = 0.016), postoperative pneumonia due to non-
fermenting Gram-negative bacilli (OR 2.28, 95% CI 1.18,
Table 1 Preoperative characteristics
Variable Patients with Patients with P-value
VAP (n =137) non-VAP (n =120)
EuroSCORE, %, mean ± SD 10.7 ± 9.9 10.2 ± 12.9 0.70
Age, yr, mean ± SD, () 68.2 ± 11.2 69.6 ± 13.0 0.34
Male gender, n (%) 98 (71.5) 86 (71.7) 0.78
Body mass index, kg/m2, mean ± SD 26.7 ± 4.6 26.1 ± 4.7 0.32
Comorbidities
Cancer, n (%) 5 (3.6) 3 (2.5) 0.60
Mediastinal irradiation, n (%) 4 (2.9) 6 (5) 0.39
Liver cirrhosis, n (%) 1 (0.7) 4 (3.3) 0.29
Decompensated liver cirrhosis, n (%) 1 (0.7) 1 (0.8) 0.99
Dyslipidemia, n (%) 62 (45.3) 55 (45.8) 0.93
COPD, n (%) 29 (21.2) 34 (28.3) 0.18
COPD with treatment, n (%) 21 (15.3) 24 (20) 0.33
Hypertension, n (%) 81 (59.1) 78 (65) 0.33
Immunosuppression, n (%)a 1 (0.7) 3 (2.5) 0.52
History of coronary artery disease, n (%) 66 (48.2) 65 (54.2) 0.34
History of congestive heart failure, n (%) 43 (31.4) 20 (16.7) 0.006
Neurologic disease, n (%)b 6 (4.4) 4 (3.3) 0.67
History of stroke, n (%) 17 (12.4) 16 (13.3) 0.83
Peripheral vascular disease, n (%) 23 (16.8) 27 (22.5) 0.25
Diabetes mellitus, n (%) 41 (29.9) 38 (31.7) 0.76
History of smoking, n (%) 67 (48.9) 70 (58.3) 0.13
Current smoking, n (%)c 14 (10.2) 27 (22.5) 0.007
Creatinine clearance, mL/min, mean ± SD 63.9 ± 26.5 65.7 ± 33.7 0.62
Chronic renal failure with dialysis, n (%) 1 (0.7) 1 (0.8) 0.99
Atrial fibrillation, n (%) 60 (43.8) 36 (30) 0.02
New York Heart Association class≥ III, n (%) 107 (78.1) 80 (66.7) 0.04
Left ventricular ejection fraction, %, mean ± SD 53 ± 15 55 ± 12 0.18
Prior antibiotic therapy, n (%) 29 (21.2) 25 (20.8) 0.95
Preoperative treatment, n (%)
Angiotensin-converting enzyme inhibitor 66 (48.2) 62 (51.7) 0.58
Betablocker 73 (53.3) 58 (48.3) 0.43
Antiplatelet therapy 80 (58.4) 76 (63.3) 0.42
Statin 74 (54) 76 (63.3) 0.13
aIncluding any immunosuppressive diseases, hematologic diseases, treatment with immunosuppressive drugs within the previous 30 days, or corticosteroids at
daily doses of at least 10 mg/day of a prednisone equivalent for more than 2 weeks. bNeurologic disease associated with functional disability. cSubject smoked an
average of at least five cigarettes per day during the month before surgery. COPD, chronic obstructive pulmonary disease; VAP, ventilator-associated pneumonia.
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0.02), time to onset of POP (OR 1.18, 95% CI 1.01, 1.39,
P = 0.04) and diabetes mellitus (OR 2.26, 95% CI 1.19,
4.30; P = 0.01). On multivariate analysis, in-hospital
mortality was significantly decreased with appropriate
empiric antibiotic therapy (OR 0.40, 95% CI 0.16, 1.00;
P = 0.05), angiotensin-converting enzyme inhibitor ther-
apy (OR 0.42, 95% CI 0.23, -0.77; P = 0.05) and anti-
biotic prophylaxis with Cefamandole (OR 0.46, 95% CI0.19, 0.93; P = 0.03). On multivariate analysis, VAP was
not associated with increased in-hospital mortality (OR
1.4. 95% CI 0.73, 2.50; P = 0.34). The Hosmer-Lemeshow
goodness-of-fit test showed good calibration of the model
(P = 0.87). The Nagelkerke and Cox/Snell R-squares were
0.29 and 0.22, respectively. Among the 162 (63% of the pa-
tients with POP) survivors, the median ICU length of stay
was 19 (12 to 28) days in the VAP group versus 13 (9 to
22) days in the non-VAP group (P = 0.006).
Table 2 Intraoperative characteristics
Variable Patients with Patients with P-value
VAP (n =137) non-VAP (n =120)
Non-scheduled surgery, n (%) 13 (9.5) 6 (5) 0.17
Redo surgery, n (%)a 22 (16.1) 12 (10) 0.15
Coronary artery bypass grafting, n (%) 61 (44.5) 64 (53.3) 0.16
Valvular surgery, n (%) 90 (65.7) 65 (54.2) 0.06
Systolic PAP, mmHg, mean ± SD 37 ± 14 35 ± 12 0.36
Congestive heart failure, n (%) 19 (13.9) 9 (7.5) 0.1
Acute renal insufficiency, n (%) 4 (2.9) 1 (0.8) 0.23
Venoarterial ECMO at the end of surgery, n (%) 5 (3.6) 2 (1.7) 0.33
Antibiotic prophylaxis with cefamandole, n (%) 115 (83.9) 104 (86.7) 0.54
Difficult endotracheal intubation, n (%) 6 (4.4) 8 (6.7) 0.42
Transesophageal echocardiography, n (%) 72 (52.6) 38 (32.7) 0.0007
Cardiopulmonary bypass time, minutes, mean ± SD 105 ± 63 76 ± 41 <0.0001
Aortic clamp time, minutes, mean ± S 69 ± 35 57 ± 29 0.002
Operating time, minutes, mean ± S 237 ± 84 200 ± 56 <0.0001
Inotropic support at the end of surgery, n (%) 88 (64.2) 50 (41.7) 0.0003
Intraoperative number of units of PRBC, n (%) 1.8 ± 2.1 1.2 ± 1.6 0.03
aCardiac surgery requiring resternotomy. ECMO, extracorporeal membrane oxygenation; PAP, pulmonary artery pressure; PRBC, packed red blood cells; VAP,
ventilator-associated pneumonia.
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This is the first study to compare VAP and non-VAP fol-
lowing CS with a special focus on microbiologic character-
istics. In the present study, incidence of POP following CS
was 3.5%, in agreement with previous studies, reporting
incidence ranging from 2% to 10% [1-4,10]. However, pre-
vious studies confined their analysis to patients with VAP,
which is not the only presentation of POP following CS,
as illustrated by previous studies in which non-VAP
represented almost 50% of all cases of POP following
CS [6,11]. Few studies have compared VAP and non-
VAP in the ICU [12-14] and only limited data are avail-
able on the antibiotic susceptibility of microorganisms
isolated in this setting.
Few differences in terms of preoperative comorbidities
were observed between the VAP and non-VAP groups,
except for a larger proportion of NYHA class ≥ III pa-
tients and a more frequent history of congestive heart
failure in the VAP group. Surgery was more difficult
(longer operating time, longer cardiopulmonary bypass
time, greater number of units of packed red blood cells
transfused, etc.) in the VAP group than in the non-VAP
group, explaining why these more severely ill patients
(as illustrated by the higher severity score) were not
extubated at the time of diagnosis of POP.
The microorganisms most commonly in this study iso-
lated were Enterobacteriaceae (35%) and non-fermenting
Gram-negative bacilli (22%) with no significant differ-
ences between the two groups of patients and accordingto the time of onset of POP. Studies evaluating POP fol-
lowing CS have reported similar results with a large
proportion of Enterobacteriaceae and non-fermenting
Gram-negative bacilli [1-4], but previous studies did
not compare VAP and non-VAP. In the study by
Esperatti et al. [12] comparing VAP and non-VAP, the
authors also reported a high incidence of non-
fermenting Gram-negative bacilli in the two groups of
patients. Similarly, Rello et al. [14] did not find any
differences in the microorganisms isolated between
the groups of patients with VAP and non-VAP and the
most commonly isolated microorganisms were Enterobac-
teriaceae (>20%) and non-fermenting Gram-negative
bacilli (>20%).
Despite a high prevalence of early-onset POP in both
groups, the most frequently prescribed antibiotic therapy
was a broad-spectrum agent targeting non-fermenting
Gram-negative bacilli (piperacillin/tazobactam in 70.4%
of cases). This policy is justified by the high frequency of
prior antibiotic use in the study population (21%) [11].
In studies evaluating POP following CS, we and others
have reported a high incidence of non-fermenting
Gram-negative bacilli, even in the first days following
surgery [1,3,6].
Few studies have evaluated empiric antibiotic therapy
in pneumonia in ICU. In the study by Rello et al. [14]
assessing empiric antibiotic therapy in VAP and non-
VAP, the most frequently prescribed antibiotic therapy in-
cluded a broad-spectrum beta-lactam antibiotic targeting
Table 3 Microorganisms isolated from 257 episodes of
postoperative pneumonia
Microorganisms, n (%) VAP Non-VAP P-value
(n =137) (n =120)
Polymicrobial infection 58 (42.3) 43 (35.8) 0.29
Non-fermenting Gram-negative bacilli 40 (29.2) 27 (22.5) 0.22
Pseudomonas aeruginosa 35 (25.5) 26 (21.7) 0.47
Acinetobacter baumannii 3 (2.2) 0 0.29
Stenotrophomonas maltophilia 2 (1.5) 1 (0.8) 0.99
Enterobacteriaceae 60 (43.8) 47 (39.2) 0.53
Escherichia coli 15 (10.9) 13 (10.8) 0.98
Enterobacter spp 14 (10.2) 6 (5) 0.12
Klebsiella spp 8 (5.8) 11 (9.2) 0.31
Hafnia alvei 4 (2.9) 4 (3.3) 0.85
Citrobacter spp 6 (4.4) 5 (4.2) 0.93
Proteus spp 7 (5.1) 6 (5) 0.97
Morganella morganii 1 (0.7) 0 0.99
Serratia marcescens 5 (3.6) 2 (1.7) 0.33
Staphylococcus aureus
Methicillin-susceptible S. aureus 14 (10.2) 4 (3.3) 0.031
Methicillin-resistant S. aureus 1 (0.7) 0 0.99
Haemophilus spp 34 (24.8) 27 (22.5) 0.66
Neisseria spp 9 (6.6) 6 (5) 0.59
Streptococcus spp 20 (14.6) 13 (10.8) 0.37
Streptococcus pneumoniae 2 (1.5) 7 (5.8) 0.057
Other streptococci 18 (13.1) 6 (5) 0.025
Total microorganisms isolated 178 124
VAP, ventilator-associated pneumonia.
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ems and 22% of piperacillin/tazobactam) regardless of the
type of pneumonia (VAP and non-VAP). The main differ-
ence was a higher proportion of carbapenems used in the
study by Rello et al. (34%), whereas in our study only 13Table 4 Susceptibility to different antimicrobial regimens of t
Antibiotics, n (%) VAP (n = 137)
Monotherapy
Amoxicillin/clavulanic acid 69 (50.4)








VAP, ventilator-associated pneumonia; 3GC, 3rd generation cephalosporins.patients (5%) received empiric antibiotic therapy including
a carbapenem. This difference could be explained by the
low and stable incidence of strains expressing extended-
spectrum β-lactamase in our ICU (2.3%). In a study by
Weber et al. [15] comparing VAP and non-VAP in ICU,
a lower incidence of non-fermenting Gram-negative ba-
cilli was observed in the non-VAP group compared to
the VAP group (14% versus 32%, P <0.02). Based on the
high incidence of resistant microorganisms, even in the
non-VAP group (14%), these authors proposed the use
of broad spectrum empiric antibiotic therapy in all
cases of POP.
Antibiotic therapy prior to the onset of pneumonia is
probably one of the most important factors associated
with the isolation of resistant microorganisms, such as
non-fermenting Gram-negative bacilli. Previous antibiotic
treatments are known risk factors for P. aeruginosa infec-
tion in VAP [16-18] and in POP following CS [11].
In our study population, the time to onset of pneu-
monia (< or ≥5 days) and the type of POP (VAP or
non-VAP) were not associated with an increased rate of
isolation of non-fermenting Gram-negative bacilli.
Similarly, Verhamme et al. [18] reported that the time
to onset of VAP was not associated with isolation of
multidrug-resistant pathogens (adjusted OR 1.1, 95%
CI, 0.6, 2.2). Interestingly, prior antibiotic therapy (ad-
justed OR 8.2, 95% CI 2.8, 23.8) and antibiotic prophylaxis
(adjusted OR 4.6, 95% CI 1.6, 13) were the strongest fac-
tors associated with the isolation of multidrug-resistant
pathogens. A high selection pressure was observed in our
study population, represented by preoperative antibiotic
therapy in 21% of cases, and systematic antibiotic
prophylaxis.
Despite a higher severity score in the ICU in the VAP
group, in-hospital mortality was not significantly differ-
ent between the two groups of patients. The absence of
significant difference between the two groups of pa-
tients could be due to a lack of power. However, nohe strains responsible for postoperative pneumonia









Table 5 Clinical characteristics of postoperative pneumonia at the time of diagnosis in the 257 patients
Variable Patients with VAP (n = 137) Patients with non-VAP (n = 120) P-value
CPIS score, mean ± SD 7.1 ± 1.2 6.9 ± 1.3 0.16
SOFA score, mean ± SD 9.1 ± 2.8 8.0 ± 3.1 0.004
Time to onset of pneumonia, days, mean ± SD 4 ± 2 4 ± 2 0.55
Peak value of cTnI, ng/mL, mean ± SD 18.7 ± 36.3 7.9 ± 11.5 0.002
Inotropic support with dobutamine, n (%) 103 (75.2) 69 (57.5) 0.003
Inotropic support with norepinephrine, n (%) 95 (69.3) 80 (66.7) 0.65
Inhaled nitrous oxide, n (%) 34 (24.8) 16 (13.3) 0.02
Number of units of PRBC, mean ± SD 2.2 ± 3.0 1.3 ± 1.9 0.005
CPIS, clinical pulmonary infection score; cTnI, cardiac troponin I; PRBC, packed red blood cells; SOFA, sequential organ failure assessment; VAP,
ventilator-associated pneumonia.
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variate analyses.
The mortality rate reported here (37%) is similar to
those observed in previous studies evaluating POP fol-
lowing CS (between 24 and 46%) [1-4]. On univariate
and in multivariate analysis, inappropriate antibiotic
therapy was associated with poorer outcome with no sig-
nificant differences between the 2 groups of patients.
Many studies have also suggested that inappropriate
antibiotic therapy for VAP is a risk factor for poorer out-
come [14,19,20]. In our study, the prognosis was poor
and similar between the two groups of patients. Previous
studies comparing VAP and non-VAP [12-14] also did
not report any difference in mortality between the two
groups of patients.
Our study had a number of limitations. The data pre-
sented here correspond to routine management and
were not specifically collected for this study. Moreover,
only documented cases of POP were taken into account;
which could lead to underestimation of the real POP
rate, particularly in non-ventilated patients, who often
present respiratory failure, therefore making the collection
of respiratory-tract samples more difficult. Nevertheless,Table 6 Risk factors independently associated with in-hospita
analysis
Variables
History of congestive heart failure
Non-fermenting Gram-negative bacilli
Age




Antibiotic prophylaxis with Cefamandole
The Hosmer-Lemeshow goodness-of-fit test showed good calibration of the model (PFagon et al. [21] and Singh et al. [22] suggest that many
non-infectious processes in postoperative patients are as-
sociated with lung infiltrates falsely attributed to pneumo-
nia that could lead to overestimation of the incidence of
pneumonia.
The conclusions based on this single-center study can-
not be extrapolated to other institutions. Single-center
studies are useful to demonstrate local ecological pat-
terns, while larger studies may show regional or even
global trends not apparent in smaller studies. All pa-
tients were included in this analysis, including those not
mechanically ventilated at the time of the diagnosis of
POP, whereas previous studies confined their analysis to
patients with VAP [1-4]. We consider that extending the
study population to non-VAP patients provides an inter-
esting perspective for physicians in this field, as VAP is
not the only clinical presentation of POP.
In the present study, only evaluating patients after CS,
all patients were intubated and mechanically ventilated
at the time of ICU admission and were extubated only
when the standard extubation criteria were obtained. In
contrast, in studies comparing VAP and non-VAP in
general ICU [12-15], the reasons for ICU admissionl mortality in the 257 patients assessed on multivariate
Adjusted odds ratio (95% CI) P-value
2.28 (1.17, 4.46) 0.02
2.28 (1.18, 4.40) 0.01
1.03 (1.01, 1.06) 0.02
1.18 (1.01, 1.39) 0.04
2.26 (1.19, 4.30) 0.01
0.40 (0.16, 1.00) 0.05
0.41 (0.23, 0.74) 0.003
0.46 (0.19, 0.93) 0.03
= 0.87). The Nagelkerke and Cox/Snell R-squares were 0.29 and 0.22, respectively.
Allou et al. Critical Care  (2015) 19:116 Page 8 of 9were variable and many patients were not intubated on
admission, which can make it difficult to compare stud-
ies dealing with CS and general ICU.
Conclusions
ICU patients with VAP are more severely ill than patients
with non-VAP following CS. Nevertheless, mortality rates
are similar between the two groups of patients. This study
suggests that empiric antibiotic regimens in patients
with pneumonia following CS should include at least a
broad-spectrum antibiotic targeting non-fermenting
Gram-negative bacilli, regardless of the type of pneu-
monia, and targeting S. aureus in VAP patients.
Key messages
 Intensive care patients with VAP are more severely
ill than non-VAP patients following CS
 Empiric antibiotic regimen should include at least a
broad-spectrum antibiotic targeting non-fermenting
Gram-negative bacilli, regardless of the type of
pneumonia
Additional file
Additional file 1: Appendix 1 Univariate analysis of risk factors for
in-hospital mortality with P < 0.10.
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